Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
about
Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.Aspects of prophylactic treatment of hemophiliaHaemophilia treatment in 2030.The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.Emerging drugs for the treatment of hemophilia A and B.2017 Clinical trials update: Innovations in hemophilia therapy.Advances in the treatment of bleeding disorders.Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations.New therapies for hemophilia.Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B.Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.Extended half-life clotting factor concentrates: results from published clinical trials.A new era for hemophilia B treatment.Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia.Haemophilia B is clinically less severe than haemophilia A: further evidence.Weekly recombinant FIX prophylaxis for severe haemophilia B in normal clinical practice: data from UKHCDO and Finland.A new modeling approach allowing prediction and comparison of the long-term outcomes of treatments for hemophilia B.Novel approaches to hemophilia therapy: successes and challenges.Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.Nonacog Beta Pegol: A Review in Haemophilia B.Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.How I manage patients with inherited haemophilia A and B and factor inhibitors.Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.Emerging therapies for hemophilia: controversies and unanswered questions.Extended Half-Life Factor VIII and Factor IX Preparations.Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia BPractical aspects of extended half-life products for the treatment of haemophilia
P2860
Q27342796-A92DEE1E-1B61-4124-BF46-891D18582C21Q28078562-0E51139A-A8BD-431D-B102-D30139DE4783Q38842671-B6E2D840-86B5-4D6F-9659-8C2F7C72F7A7Q38867485-A1B19B76-6289-488C-8DA5-79DD54FA4722Q38933707-0CFE773A-0419-4A5B-B6AC-66F95BB32DB9Q38937725-702AF853-AB15-4153-8454-5E7C1C60898EQ38945123-B71E9694-86C6-49B8-9DF6-24D73FAA7D31Q38961683-1816FE89-3939-4A54-982C-077AEC057569Q39027887-65F798CF-9D16-4F5E-95A7-C3116FB91BE6Q39042380-0F79ACA6-9B84-4A10-BA02-3107675FF38FQ39204747-E5E50CB5-DD8F-4189-83EA-C6529F5C25CAQ39499567-978A5CF4-71B7-41CD-BFE0-DCAAD15B1BCCQ39609294-5A4BF78D-A294-4E2A-B296-5B467D38D1F8Q39979927-E86C3496-FEBD-4D97-9AEF-26B837FEF3F9Q45855493-25682E0D-3B0F-4D49-91EB-009834B0C41AQ45858664-F5248C28-CC93-44CB-A0B9-2501FAE85DBFQ45859023-2CAA56F4-15E8-4AB2-96D0-6B747E94F636Q45867846-C89B7760-7C31-4350-A76A-BE4E55EE5C83Q45868343-AE4A3684-1A69-419E-B3CD-21D1A7D18D33Q45873013-034720C8-15CE-45FA-ABA3-667EB929F400Q45874183-E09D1603-9483-4F6C-9062-7DB3E448EEB4Q45874270-2DCA189B-4234-44B4-B4B5-1E33D1D44A8BQ47287713-9263F4F5-CC73-47B7-A002-5DC1508C3197Q48359988-60EBBEF7-F676-403F-941D-398712ADDDA2Q52663655-9FA4DFA3-BEB3-4905-96B0-42D942C71BE3Q54958581-F354FA39-5234-43C4-95D2-B316FC8EE769Q55025596-4FF956A5-95BC-42D3-916E-1998C0978799Q55313906-5323B592-7B61-4986-A1FE-5D2945E757E4Q55617834-43939BB5-ECA6-4157-9243-4A2E2148E737Q58583115-96BFE09B-3417-442A-A413-0BB65D62AFA3Q58761664-C33FF68C-63A2-477A-91EF-07978AB35926
P2860
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Long-acting recombinant coagul ...... B: results of a phase 3 trial.
@ast
Long-acting recombinant coagul ...... B: results of a phase 3 trial.
@en
type
label
Long-acting recombinant coagul ...... B: results of a phase 3 trial.
@ast
Long-acting recombinant coagul ...... B: results of a phase 3 trial.
@en
prefLabel
Long-acting recombinant coagul ...... B: results of a phase 3 trial.
@ast
Long-acting recombinant coagul ...... B: results of a phase 3 trial.
@en
P2093
P2860
P921
P1433
P1476
Long-acting recombinant coagul ...... B: results of a phase 3 trial.
@en
P2093
Brigitte Pan-Petesch
Carmen Altisent
Christine Voigt
Claude Negrier
Elena Santagostino
Giancarlo Castaman
Hideji Hanabusa
Iris Jacobs
Johannes Oldenburg
Koji Yamamoto
P2860
P304
P356
10.1182/BLOOD-2015-09-669234
P407
P577
2016-01-11T00:00:00Z